Vascular cell adhesion molecule-1 (VCAM-1)—An increasing insight into its role in tumorigenicity and metastasis
Corresponding Author
Martin Schlesinger
Department of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, 53121 Bonn, Germany
Correspondence to: Dr. Martin Schlesinger, Department of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany, Tel.: +49-228-735238, Fax: +49-228-734692, E-mail: [email protected]Search for more papers by this authorGerd Bendas
Department of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, 53121 Bonn, Germany
Search for more papers by this authorCorresponding Author
Martin Schlesinger
Department of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, 53121 Bonn, Germany
Correspondence to: Dr. Martin Schlesinger, Department of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany, Tel.: +49-228-735238, Fax: +49-228-734692, E-mail: [email protected]Search for more papers by this authorGerd Bendas
Department of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, 53121 Bonn, Germany
Search for more papers by this authorAbstract
Vascular cell adhesion molecule-1 (VCAM-1) first attracted attention more than two decades ago as endothelial adhesion receptor with key function for leukocyte recruitment in term of cellular immune response. The early finding of VCAM-1 binding to melanoma cells, and thus a suggested mechanistic contribution to metastatic spread, was the first and for a long time the only link of VCAM-1 to cancer sciences. In the last few years, hallmarked by a growing insight into the molecular understanding of tumorigenicity and metastasis, an impressive variety of VCAM-1 functionalities in cancer have been elucidated. The present review aims to provide a current overview of VCAM-1 relevance for tumor growth, metastasis, angiogenesis, and related processes. By illustrating the intriguing role of VCAM-1 in cancer disease, VCAM-1 is suggested as a new and up to now underestimated target in cancer treatment and in clinical diagnosis of malignancies.
References
- 1 Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989; 59: 1203–11.
- 2 Rice GE, Bevilacqua MP. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 1989; 246: 1303–6.
- 3 Wittchen ES. Endothelial signaling in paracellular and transcellular leukocyte transmigration. Front Biosci Landmark Ed 2009; 14: 2522–45.
- 4 Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678–89.
- 5 Gurtner GC, Davis V, Li H, et al. Targeted disruption of the murine VCAM1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation. Genes Dev 1995; 9: 1–14.
- 6 Alvarez P, Carrillo E, Vélez C, et al. Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing. BioMed Res Int 2013; 2013: 312656.
- 7 Craddock CF, Nakamoto B, Andrews RG, et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997; 90: 4779–88.
- 8 Freedman AS, Munro JM, Rice GE, et al. Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science 1990; 249: 1030–3.
- 9 Walsh GM, Symon FA, Lazarovils AL, et al. Integrin alpha 4 beta 7 mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin. Immunology 1996; 89: 112–9.
- 10 Chiu HH, Crowe DT, Renz ME, et al. Similar but nonidentical amino acid residues on vascular cell adhesion molecule-1 are involved in the interaction with alpha 4 beta 1 and alpha 4 beta 7 under different activity states. J Immunol Baltim Md 1950 1995; 155: 5257–67.
- 11 Kilger G, Needham LA, Nielsen PJ, et al. Differential regulation of integrin-dependent binding to domains 1 and 4 of vascular cell adhesion molecule-1. J Biol Chem 1995; 270: 5979–84.
- 12 Costa MFS, Bornstein VU, Candéa AL, et al. CCL25 induces α4,β7, integrin-dependent migration of IL-17+ γδ T lymphocytes during an allergic reaction. Eur J Immunol 2012; 42: 1250–60.
- 13 Barthel SR, Jarjour NN, Mosher DF, et al. Dissection of the hyperadhesive phenotype of airway eosinophils in asthma. Am J Respir Cell Mol Biol 2006; 35: 378–86.
- 14 Barthel SR, Annis DS, Mosher DF, et al. Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins α4β1 (CD49d/29) and αMβ2 (CD11b/18) of eosinophils. J Biol Chem 2006; 281: 32175–87.
- 15 Kon S, Atakilit A, Sheppard D. Short form of α9 promotes α9β1 integrin-dependent cell adhesion by modulating the function of the full-length α9 subunit. Exp Cell Res 2011; 317: 1774–84.
- 16 Grayson MH, Van der Vieren M, Sterbinsky SA, et al. alphadbeta2 integrin is expressed on human eosinophils and functions as an alternative ligand for vascular cell adhesion molecule 1 (VCAM-1). J Exp Med 1998; 188: 2187–91.
- 17 Marchese ME, Berdnikovs S, Cook-Mills JM. Distinct sites within the vascular cell adhesion molecule-1 (VCAM-1) cytoplasmic domain regulate VCAM-1 activation of calcium fluxes versus Rac1 during leukocyte transendothelial migration. Biochemistry (Mosc) 2012; 51: 8235–46.
- 18 Barreiro O, Yáñez-Mó M, Sala-Valdés M, et al. Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation. Blood 2005; 105: 2852–61.
- 19 Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005; 6: 801–11.
- 20 Cook-Mills JM, Marchese ME, Abdala-Valencia H. Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants. Antioxid Redox Signal 2011; 15: 1607–38.
- 21 Cybulsky MI, Fries JW, Williams AJ, et al. Alternative splicing of human VCAM-1 in activated vascular endothelium. Am J Pathol 1991; 138: 815–20.
- 22 Cybulsky MI, Fries JW, Williams AJ, et al. Gene structure, #chromosomal |location, and basis for alternative mRNA splicing of the human VCAM1 gene. Proc Natl Acad Sci USA 1991; 88: 7859–63.
- 23 Hession C, Tizard R, Vassallo C, et al. Cloning of an alternate form of vascular cell adhesion molecule-1 (VCAM1). J Biol Chem 1991; 266: 6682–5.
- 24 Osborn L, Vassallo C, Benjamin CD. Activated endothelium binds lymphocytes through a novel binding site in the alternately spliced domain of vascular cell adhesion molecule-1. J Exp Med 1992; 176: 99–107.
- 25 Vonderheide RH, Springer TA. Lymphocyte adhesion through very late antigen 4: evidence for a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule 1 and an additional alpha 4 integrin counter-receptor on stimulated endothelium. J Exp Med 1992; 175: 1433–42.
- 26 Woodside DG, Kram RM, Mitchell JS, et al. Contrasting roles for domain 4 of VCAM-1 in the regulation of cell adhesion and soluble VCAM-1 binding to integrin alpha4beta1. J Immunol Baltim Md 1950 2006; 176: 5041–9.
- 27 Barreiro O, Yanez-Mo M, Serrador JM, et al. Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol 2002; 157: 1233–45.
- 28 Wójciak-Stothard B, Williams L, Ridley AJ. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol 1999; 145: 1293–307.
- 29 Yamada Y, Arao T, Matsumoto K, et al. Plasma concentrations of VCAM-1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer. Cancer Sci 2010; 101: 1886–90.
- 30 Mackay F, Loetscher H, Stueber D, et al. Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 1993; 177: 1277–86.
- 31 Lee YW, Kühn H, Hennig B, et al. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J Mol Cell Cardiol 2001; 33: 83–94.
- 32 Yoshida N, Manabe H, Terasawa Y, et al. Inhibitory effects of vitamin E on endothelial-dependent adhesive interactions with leukocytes induced by oxidized low density lipoprotein. BioFactors Oxf Engl 2000; 13: 279–88.
- 33 Piga R, Naito Y, Kokura S, et al. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis 2007; 193: 328–34.
- 34 Piga R, Naito Y, Kokura S, et al. Inhibitory effect of serotonin derivatives on high glucose-induced adhesion and migration of monocytes on human aortic endothelial cells. Br J Nutr 2009; 102: 264–72.
- 35 Hortelano S, López-Fontal R, Través PG, et al. ILK mediates LPS-induced vascular adhesion receptor expression and subsequent leucocyte trans-endothelial migration. Cardiovasc Res 2010; 86: 283–92.
- 36 Zeuke S, Ulmer AJ, Kusumoto S, et al. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res 2002; 56: 126–34.
- 37 Schill T, Schön MP, Pletz N, et al. Stimulation of pulmonary immune responses by the TLR2/6 agonist MALP-2 and effect on melanoma metastasis to the lung. Exp Dermatol 2012; 21: 91–8.
- 38 Haddad O, Chotard-Ghodsnia R, Verdier C, et al. Tumor cell/endothelial cell tight contact upregulates endothelial adhesion molecule expression mediated by NFkappaB: differential role of the shear stress. Exp Cell Res 2010; 316: 615–26.
- 39 Rice GE, Munro JM, Corless C, et al. Vascular and nonvascular expression of INCAM-110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissues. Am J Pathol 1991; 138: 385–93.
- 40 Allavena R, Noy S, Andrews M, et al. CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis. Am J Pathol 2010; 176: 556–62.
- 41 Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107: 1255–62.
- 42 Stanley AC, Dalton JE, Rossotti SH, et al. VCAM-1 and VLA-4 modulate dendritic cell IL-12p40 production in experimental visceral leishmaniasis. PLoS Pathog 2008; 4: e1000158.
- 43 Rice GE, Gimbrone MA, Jr, Bevilacqua MP. Tumor cell-endothelial interactions. Increased adhesion of human melanoma cells to activated vascular endothelium. Am J Pathol 1988; 133: 204–10.
- 44 Taichman DB, Cybulsky MI, Djaffar I, et al. Tumor cell surface alpha 4 beta 1 integrin mediates adhesion to vascular endothelium: demonstration of an interaction with the N-terminal domains of INCAM-110/VCAM-1. Cell Regul 1991; 2: 347–55.
- 45 Juneja HS, Schmalsteig FC, Lee S, et al. Vascular cell adhesion molecule-1 and VLA-4 are obligatory adhesion proteins in the heterotypic adherence between human leukemia/lymphoma cells and marrow stromal cells. Exp Hematol 1993; 21: 444–50.
- 46 Martìn-Padura I, Mortarini R, Lauri D, et al. Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression. Cancer Res 1991; 51: 2239–41.
- 47 Garofalo A, Chirivi RG, Foglieni C, et al. Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Res 1995; 55: 414–9.
- 48 Okahara H, Yagita H, Miyake K, et al. Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis. Cancer Res 1994; 54: 3233–6.
- 49 Cardones AR, Murakami T, Hwang ST. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res 2003; 63: 6751–7.
- 50 Higashiyama A, Watanabe H, Okumura K, et al. Involvement of tumor necrosis factor alpha and very late activation antigen 4/vascular cell adhesion molecule 1 interaction in surgical-stress-enhanced experimental metastasis. Cancer Immunol Immunother CII 1996; 42: 231–6.
- 51 Klemke M, Weschenfelder T, Konstandin MH, et al. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J Cell Physiol 2007; 212: 368–74.
- 52 Chan PY, Aruffo A. VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J Biol Chem 1993; 268: 24655–64.
- 53 Huang AJ, Manning JE, Bandak TM, et al. Endothelial cell cytosolic free calcium regulates neutrophil migration across monolayers of endothelial cells. J Cell Biol 1993; 120: 1371–80.
- 54 Matheny HE, Deem TL, Cook-Mills JM. Lymphocyte migration through monolayers of endothelial cell lines involves VCAM-1 signaling via endothelial cell NADPH oxidase. J Immunol 2000; 164: 6550–9.
- 55
Cook-Mills JM. Isoforms of vitamin E differentially regulate PKC α and inflammation: a review. J Clin Cell Immunol 2013; 4: 137.
10.4172/2155-9899.1000137 Google Scholar
- 56 Cook-Mills JM, Johnson JD, Deem TL, et al. Calcium mobilization and Rac1 activation are required for VCAM-1 (vascular cell adhesion molecule-1) stimulation of NADPH oxidase activity. Biochem J 2004; 378: 539–47.
- 57 Deem TL, Cook-Mills JM. Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species. Blood 2004; 104: 2385–93.
- 58 Keshavan P, Deem TL, Schwemberger SJ, et al. Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. J Immunol 2005; 174: 3709–18.
- 59 Lee S, Yoon I-H, Yoon A, et al. An antibody to the sixth Ig-like domain of VCAM-1 inhibits leukocyte transendothelial migration without affecting adhesion. J Immunol Baltim Md 1950 2012; 189: 4592–601.
- 60 Partridge J, Carlsen H, Enesa K, et al. Laminar shear stress acts as a switch to regulate divergent functions of NF-kappaB in endothelial cells. FASEB J Off Publ Fed Am Soc Exp Biol 2007; 21: 3553–61.
- 61 Chiu J-J, Chen L-J, Lee P-L, et al. Shear stress inhibits adhesion molecule expression in vascular endothelial cells induced by coculture with smooth muscle cells. Blood 2003; 101: 2667–74.
- 62 Chiu J-J, Lee P-L, Chen C-N, et al. Shear stress increases ICAM-1 and decreases VCAM-1 and E-selectin expressions induced by tumor necrosis factor-[alpha] in endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24: 73–9.
- 63 Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2012; 2: 1091–9.
- 64 Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123–34.
- 65 Karshovska E, Weber C, von Hundelshausen P. Platelet chemokines in health and disease. Thromb Haemost 2013; 110: 894–902.
- 66 Von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27–40.
- 67 Massberg S, Konrad I, Schürzinger K, et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 2006; 203: 1221–33.
- 68 Ludwig RJ, Schultz JE, Boehncke W-H, et al. Activated, #not |resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 2004; 122: 830–6.
- 69 Dole VS, Bergmeier W, Mitchell HA, et al. Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood 2005; 106: 2334–9.
- 70 Khatib A-M, Auguste P, Fallavollita L, et al. Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol 2005; 167: 749–59.
- 71 Damle NK, Eberhardt C, Van der Vieren M. Direct interaction with primed CD4+ CD45R0+ memory T lymphocytes induces expression of endothelial leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1 on the surface of vascular endothelial cells. Eur J Immunol 1991; 21: 2915–23.
- 72 Damle NK, Doyle LV. Stimulation of cloned human T lymphocytes via the CD3 or CD28 molecules induces enhancement in vascular endothelial permeability to macromolecules with participation of type-1 and type-2 intercellular adhesion pathways. Eur J Immunol 1990; 20: 1995–2003.
- 73 Qi J, Chen N, Wang J, et al. Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol Biol Cell 2005; 16: 4386–97.
- 74 Jones J, Berkhoff S, Weich E, et al. Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes. J Cell Mol Med 2007; 11: 826–38.
- 75 Langley RR, Carlisle R, Ma L, et al. Endothelial expression of vascular cell adhesion molecule-1 correlates with metastatic pattern in spontaneous melanoma. Microcirc N Y N 1994 2001; 8: 335–45.
- 76 Simiantonaki N, Jayasinghe C, Kirkpatrick CJ. Effect of pro-inflammatory stimuli on tumor cell-mediated induction of endothelial cell adhesion molecules in vitro. Exp Mol Pathol 2002; 73: 46–53.
- 77 Sipos E, Chen L, András IE, et al. Proinflammatory adhesion molecules facilitate polychlorinated biphenyl-mediated enhancement of brain metastasis formation. Toxicol Sci Off J Soc Toxicol 2012; 126: 362–71.
- 78 Läubli H, Spanaus K-S, Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 2009; 114: 4583–91.
- 79 Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50–6.
- 80 Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011; 11: 597–606.
- 81 Williams SA, Harata-Lee Y, Comerford I, et al. Multiple functions of CXCL12 in a syngeneic model of breast cancer. Mol Cancer 2010; 9: 250.
- 82 Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13: 265–70.
- 83 Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004; 14: 149–54.
- 84 Zhao L, Lim SY, Gordon-Weeks AN, et al. Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatol Baltim Md 2013; 57: 829–39.
- 85 Lim SY, Gordon-Weeks AN, Zhao L, et al. Recruitment of myeloid cells to the tumor microenvironment supports liver metastasis. Oncoimmunology 2013; 2: e23187.
- 86 Qian B-Z, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222–5.
- 87 Qian B, Deng Y, Im JH, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PloS One 2009; 4: e6562.
- 88 Wolf MJ, Hoos A, Bauer J, et al. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 2012; 22: 91–105.
- 89 Gil-Bernabé AM, Ferjancic S, Tlalka M, et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 2012; 119: 3164–75.
- 90 Ferjancic S, Gil-Bernabé AM, Hill SA, et al. VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice. Blood 2013; 121: 3289–97.
- 91 Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–6.
- 92 Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149–53.
- 93 Piali L, Fichtel A, Terpe HJ, et al. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995; 181: 811–6.
- 94 Griffioen AW, Tromp SC, Hillen HF. Angiogenesis modulates the tumour immune response. Int J Exp Pathol 1998; 79: 363–8.
- 95 Griffioen AW, Damen CA, Blijham GH, et al. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996; 88: 667–73.
- 96 Dirkx AEM, Oude Egbrink MGA, Kuijpers MJE, et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 2003; 63: 2322–9.
- 97 Dirkx AEM, Oude Egbrink MGA, Wagstaff J, et al. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 2006; 80: 1183–96.
- 98 Delfortrie S, Pinte S, Mattot V, et al. Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. Cancer Res 2011; 71: 7176–86.
- 99 Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001; 276: 7614–20.
- 100 Melder RJ, Koenig GC, Witwer BP, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996; 2: 992–7.
- 101 Detmar M, Brown LF, Schön MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998; 111: 1–6.
- 102 Wang H-T, Lee H-I, Guo J-H, et al. Calreticulin promotes tumor lymphocyte infiltration and enhances the antitumor effects of immunotherapy by up-regulating the endothelial expression of adhesion molecules. Int J Cancer J Int Cancer 2012; 130: 2892–902.
- 103 Chen Q, Zhang XH-F, Massagué J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 2011; 20: 538–49.
- 104 Lin K-Y, Lu D, Hung C-F, et al. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007; 67: 1832–41.
- 105 Kuai W-X, Wang Q, Yang X-Z, et al. Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells. World J Gastroenterol WJG 2012; 18: 979–85.
- 106 Ding Y-B, Chen G-Y, Xia J-G, et al. Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J Gastroenterol WJG 2003; 9: 1409–14.
- 107 Gupta GP, Minn AJ, Kang Y, et al. Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol 2005; 70: 149–58.
- 108 Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518–24.
- 109 Lu X, Mu E, Wei Y, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell 2011; 20: 701–14.
- 110 Chen Q, Massagué J. Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clin Cancer Res Off J Am Assoc Cancer Res 2012; 18: 5520–5.
- 111 Hynes RO. Metastatic cells will take any help they can get. Cancer Cell 2011; 20: 689–90.
- 112 Gil-Bernabé AM, Ferjancic S, Tlalka M, et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 2012; 119: 3164–75.
- 113 Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39–51.
- 114 Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995; 92: 11671–5.
- 115 Wu T-C. The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 2007; 67: 6003–6.
- 116 Rose DM, Grabovsky V, Alon R, Ginsberg MH. The affinity of integrin alpha(4)beta(1) governs lymphocyte migration. J Immunol Baltim Md 1950 2001; 167: 2824–30.
- 117 Rose DM, Han J, Ginsberg MH. Alpha4 integrins and the immune response. Immunol Rev 2002; 186: 118–24.
- 118 Han J, Rose DM, Woodside DG, et al. Integrin alpha 4 beta 1-dependent T cell migration requires both phosphorylation and dephosphorylation of the alpha 4 cytoplasmic domain to regulate the reversible binding of paxillin. J Biol Chem 2003; 278: 34845–53.
- 119 Liu S, Thomas SM, Woodside DG, et al. Binding of paxillin to alpha4 integrins modifies integrin-dependent biological responses. Nature 1999; 402: 676–81.
- 120 Kassner PD, Alon R, Springer TA, et al. Specialized functional properties of the integrin alpha 4 cytoplasmic domain. Mol Biol Cell 1995; 6: 661–74.
- 121 Rose DM, Liu S, Woodside DG, et al. Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol Baltim Md 1950 2003; 170: 5912–8.
- 122 Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008; 8: 604–17.
- 123 Garmy-Susini B, Varner JA. Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphat Res Biol 2008; 6: 155–63.
- 124 Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144: 789–801.
- 125 Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98: 769–78.
- 126 Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999; 154: 385–94.
- 127 Garmy-Susini B, Avraamides CJ, Desgrosellier JS, et al. PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci USA 2013; 110: 9042–7.
- 128 Garmy-Susini B, Avraamides CJ, Schmid MC, et al. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res 2010; 70: 3042–51.
- 129 Rebhun RB, Cheng H, Gershenwald JE, et al. Constitutive expression of the alpha4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma. Neoplasia N Y N 2010; 12: 173–82.
- 130 Testaz S, Duband JL. Central role of the alpha4beta1 integrin in the coordination of avian truncal neural crest cell adhesion, migration, and survival. Dev Dyn Off Publ Am Assoc Anat 2001; 222: 127–40.
- 131 Leu ST, Jacques SAL, Wingerd KL, et al. Integrin alpha4beta1 function is required for cell survival in developing retina. Dev Biol 2004; 276: 416–30.
- 132 Callery C, Cochran AJ, Roe DJ, et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surg 1982; 196: 69–75.
- 133 Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol Off J Am Soc Clin Oncol 1988; 6: 163–72.
- 134 Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506–12.
- 135 Turhan H, Erbay AR, Yasar AS, et al. Plasma soluble adhesion molecules: intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin levels in patients with isolated coronary artery ectasia. Coron Artery Dis 2005; 16: 45–50.
- 136 Wellicome SM, Kapahi P, Mason JC, et al. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993; 92: 412–8.
- 137 Mason JC, Kapahi P, Haskard DO. Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Lack of correlation with levels of circulating vascular cell adhesion molecule 1. Arthritis Rheum 1993; 36: 519–27.
- 138 Gearing AJ, Hemingway I, Pigott R, et al. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann N Y Acad Sci 1992; 667: 324–31.
- 139 Matsuno O, Miyazaki E, Nureki S, et al. Role of ADAM8 in experimental asthma. Immunol Lett 2006; 102: 67–73.
- 140 Matsuno O, Miyazaki E, Nureki S, et al. Elevated soluble ADAM8 in bronchoalveolar lavage fluid in patients with eosinophilic pneumonia. Int Arch Allergy Immunol 2007; 142: 285–90.
- 141 Guaiquil V, Swendeman S, Yoshida T, et al. ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol 2009; 29: 2694–703.
- 142 Peduto L. ADAM9 as a potential target molecule in cancer. Curr Pharm Des 2009; 15: 2282–7.
- 143 Fröhlich C, Klitgaard M, Noer JB, et al. ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins. Biochem J 2013; 452: 97–109.
- 144 Garton KJ, Gough PJ, Philalay J, et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 2003; 278: 37459–64.
- 145 Banks RE, Gearing AJ, Hemingway IK, et al. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 1993; 68: 122–4.
- 146 O'Hanlon DM, Fitzsimons H, Lynch J, et al. Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer Oxf Engl 1990 2002; 38: 2252–7.
- 147 Miaskowski C, Dodd M, Paul SM, et al. Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery. PloS One 2013; 8: e60164.
- 148 Eggeman H, Stöblen F, Thill M, et al. Influence of a dose-dense adjuvant chemotherapy on sVCAM-1/sICAM-1 serum levels in breast cancer patients with 1-3 positive lymph nodes. Anticancer Res 2011; 31: 2617–22.
- 149 Dymicka-Piekarska V, Guzinska-Ustymowicz K, Kuklinski A, et al. Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients. Thromb Res 2012; 129: e47–50.
- 150 Liu Y, Starr MD, Bulusu A, et al. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med 2013; 2: 234–42.
- 151 Velikova G, Banks RE, Gearing A, et al. Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer 1998; 77: 1857–63.
- 152 Velikova G, Banks RE, Gearing A, et al. Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancer. Br J Cancer 1997; 76: 1398–404.
- 153 Shioi K, Komiya A, Hattori K, et al. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients. Clin Cancer Res Off J Am Assoc Cancer Res 2006; 12: 7339–46.
- 154 Van der Veldt AAM, Vroling L, de Haas RR, et al. Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer. Int J Cancer J Int Cancer 2012; 131: E484–93.
- 155 Huang J, Zhang J, Li H, et al. VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer. Am J Transl Res 2013; 5: 336–46.
- 156 Shah N, Cabanillas F, McIntyre B, et al. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma 2012; 53: 50–6.
- 157 Montes-Sánchez D, Ventura JL, Mitre I, et al. Glycosylated VCAM-1 isoforms revealed in 2D western blots of HUVECs treated with tumoral soluble factors of breast cancer cells. BMC Chem Biol 2009; 9: 7.
- 158 Min TJ, Park S-H, Ji Y-H, et al. Morphine attenuates endothelial cell adhesion molecules induced by the supernatant of LPS-stimulated colon cancer cells. J Korean Med Sci 2011; 26: 747–52.
- 159 Salado C, Olaso E, Gallot N, et al. Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl Med 2011; 9: 59.
- 160 Wagner BJ, Löb S, Lindau D, et al. Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin. Int J Oncol 2011; 39: 1593–600.
- 161 Ridgway LD, Wetzel MD, Ngo JA, et al. Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells. Mol Cancer Res MCR 2012; 10: 689–702.
- 162 Chanvorachote P, Chunhacha P. Caveolin-1 regulates endothelial adhesion of lung cancer cells via reactive oxygen species-dependent mechanism. PloS One 2013; 8: e57466.
- 163 Bloemen PG, Henricks PA, van Bloois L, et al. Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett 1995; 357: 140–4.
- 164 Gosk S, Moos T, Gottstein C, et al. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 2008; 1778: 854–63.
- 165 Voinea M, Manduteanu I, Dragomir E, et al. Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells—a potential tool for specific drug delivery. Pharm Res 2005; 22: 1906–17.
- 166 Kang DI, Lee S, Lee JT, et al. Preparation and in vitro evaluation of anti-VCAM-1-Fab'-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib. J Microencapsul 2011; 28: 220–7.
- 167 Han SG, Newsome B, Hennig B. Titanium dioxide nanoparticles increase inflammatory responses in vascular endothelial cells. Toxicology 2013; 306: 1–8.
- 168 Morral-Ruíz G, Melgar-Lesmes P, Solans C, et al. Multifunctional polyurethane-urea nanoparticles to target and arrest inflamed vascular environment: a potential tool for cancer therapy and diagnosis. J Control Release Off J Control Release Soc 2013; 171: 163–71.
- 169 Kusunose J, Gagnon MKJ, Seo JW, Ferrara KW. Quantitation of nanoparticle accumulation in flow using optimized microfluidic chambers. J Drug Target 2013; 22: 48–56.
- 170 Rouleau L, Berti R, Ng VWK, et al. VCAM-1-targeting gold nanoshell probe for photoacoustic imaging of atherosclerotic plaque in mice. Contrast Media Mol Imaging 2013; 8: 27–39.
- 171 Yang H, Zhao F, Li Y, et al. VCAM-1-targeted core/shell nanoparticles for selective adhesion and delivery to endothelial cells with lipopolysaccharide-induced inflammation under shear flow and cellular magnetic resonance imaging in vitro. Int J Nanomedicine 2013; 8: 1897–906.
- 172 Fréchou M, Beray-Berthat V, Raynaud J-S, et al. Detection of vascular cell adhesion molecule-1 expression with USPIO-enhanced molecular MRI in a mouse model of cerebral ischemia. Contrast Media Mol Imaging 2013; 8: 157–64.
- 173 Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006; 114: 1504–11.
- 174 Hamilton AJ, Huang S-L, Warnick D, et al. Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol 2004; 43: 453–60.
- 175 Serres S, Soto MS, Hamilton A, et al. Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci USA 2012; 109: 6674–9.
- 176 McAteer MA, Sibson NR, von Zur Muhlen C, et al. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med 2007; 13: 1253–8.
- 177 Rudick R, Polman C, Clifford D, et al. Natalizumab: bench to bedside and beyond. JAMA Neurol 2013; 70: 172–82.
- 178 Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol 2013; 264: 123–6.
- 179 Schlesinger M, Schmitz P, Zeisig R, et al. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives. Thromb Res 2012; 129: 603–10.
- 180 Vanderslice P, Biediger RJ, Woodside DG, et al. Development of cell adhesion molecule antagonists as therapeutics for asthma and COPD. Pulm Pharmacol Ther 2004; 17: 1–10.
- 181 Podar K, Zimmerhackl A, Fulciniti M, et al. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol 2011; 155: 438–48.
- 182 Mori Y, Shimizu N, Dallas M, et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004; 104: 2149–54.
- 183 Monaco MCG, Major EO. The link between VLA-4 and JC virus reactivation. Expert Rev Clin Immunol 2012; 8: 63–72.
- 184 Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler Houndmills Basingstoke Engl 2012; 18: 143–52.